



Aalborg University Hospital in Denmark Selects EOS for 2D/3D Imaging

EOS imaging system is now installed at Northern Denmark's largest university hospital

Paris, September 2, 2014 - EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopaedic medical imaging, today announced the installation of an EOS® imaging system at the Aalborg University Hospital (AUH) in Denmark, the largest hospital in the northern Denmark region. AUH is the second hospital in Denmark to install EOS equipment.

As the region's largest hospital, the Aalborg University Hospital plays a central role in the cooperative North Denmark healthcare system, serving more than 1.1 million patients throughout northern and central Denmark. The hospital maintains Danish Quality Model (DDKM) accreditation and is among the largest employers in the region with more than 6,500 employees.

Søren Eiskjær, Chief Spine Surgeon, Department of Orthopedic Surgery, Aalborg University Hospital said, *"We have a responsibility to the patients we serve, as part of the Danish healthcare system, to provide access to optimal technology for delivering the best possible treatment outcome, while also holding the best clinical research potential. Our decision to install an EOS system was guided by this commitment."*

The EOS system provides full-body images of patients in a natural standing or seated position in both 2D and 3D with 50% to 85% less dose than Digital Radiology and 95% less dose than basic CT scans, in accordance with the ALARA (As Low As Reasonably Achievable) principle of radiation reduction. This comprehensive yet low dose imaging makes EOS imaging ideal for pediatric patients who require frequent treatment monitoring.

Marie Meynadier, CEO of EOS imaging, said, *"This EOS installation in a second leading Danish university hospital increases our presence and continued technology adoption in Northern Europe. Aalborg University Hospital's decision to rely on EOS for 2D/3D orthopaedic imaging speaks to growing level of the trust and credibility that has been established among EOS imaging and academic medical institutions."*

For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit <http://www.eos-imaging.com/>.

About EOS imaging:

EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 32 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of more than 90 sites and by more than 500,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 106 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), in Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.

EOS imaging is listed on Compartment C of Euronext Paris

ISIN: FR0011191766 – Ticker: EOSI

Next press release: revenue for the 3rd quarter of 2014, on October 22, 2014 (after market).



Contacts:

Anne Renevot

CFO

Ph: +33 (0)1 55 25 61 24

investors@eos-imaging.com

NewCap

Financial communication and investor relations

Sophie Boullila / Pierre Laurent

Ph: +33 (0)1 44 71 94 91 - eosimaging@newcap.fr

The Ruth Group (US)

Press relations / Melanie Sollid-Penton

Ph: 646-536-7023

msollid@theruthgroup.com